API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 134 articles Forum Github 13 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. SA /
  3. BIOM3.SA

Biomm S.A (BIOM3 SA) stock market data APIs

R$9.99 0.05(0.5%) as of September 13, 2024
Price chart is built with Anychart

Biomm S.A. operates as a biotechnology company in Brazil. The company offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. Biomm S.A. was founded in 2001 and is headquartered in Nova Lima, Brazil.

Biomm S.A Financial Data Overview

9.94
9.99
-
10.15
9.84
4.03-21.2
1 261 M
127 M
124 M
-0.3285
0.818
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'BIOM3',
Type: 'Common Stock',
Name: 'Biomm S.A',
Exchange: 'SA',
CurrencyCode: 'BRL',
CurrencyName: 'Brazilian real',
CurrencySymbol: 'R$',
CountryName: 'Brazil',
CountryISO: 'BR',
OpenFigi: NULL,
ISIN: 'BRBIOMACNOR2',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Biomm S.A Fundamental Data is available in our Financial Data APIs

  • Net Revenue 124 M
  • EBITDA -64 976 000
  • Earnings Per Share -0.98
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Biomm S.A Earnings via APIs

  • Latest Release 2022-06-30
  • EPS/Forecast NaN

Get Biomm S.A End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Biomm S.A latest news via APIs

Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days

VANCOUVER, Washington, May 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140)...
  • BIOMM S.A
  • BIOTECHNOLOGY COMPANY
  • BRAZIL
  • CLINICAL TRIAL
  • CLINICAL TRIALS
  • COMPANY
  • CYTODYN INC
  • HIV-INFECTED PATIENTS
  • THE COMPANY
  • THERAPEUTIC INDICATIONS

Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days

VANCOUVER, Washington, May 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140)...
  • BIOMM S.A
  • BIOTECHNOLOGY COMPANY
  • BRAZIL
  • CLINICAL TRIAL
  • CLINICAL TRIALS
  • COMPANY
  • CYTODYN INC
  • HIV-INFECTED PATIENTS
  • THE COMPANY
  • THERAPEUTIC INDICATIONS
Do you have any questions?
support@eodhistoricaldata.com